Get the Stockscreener App
25.47
0.12%
0.03
After Hours:
25.68
0.21
+0.82%
Bicara Therapeutics Inc stock is traded at $25.47, with a volume of 189.07K.
It is up +0.12% in the last 24 hours and up +0.00% over the past month.
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
See More
Previous Close:
$25.44
Open:
$25.44
24h Volume:
189.07K
Relative Volume:
2.97
Market Cap:
$1.36B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-0.24%
1M Performance:
+0.00%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$23.75
$25.68
1-Week Range:
$23.75
$27.45
52-Week Range:
$22.12
$27.94
Bicara Therapeutics Inc Stock (BCAX) Company Profile
Name
Bicara Therapeutics Inc
Sector
Industry
Phone
-
Address
-
Bicara Therapeutics Inc Stock (BCAX) Latest News
Bicara Therapeutics, Adecoagro, and More Stocks See Action From Activist Investors - Barron's
With IPO, have the capital and resources for clinical studies: Bicara CEO - The Economic Times
Bicara Therapeutics Rings the Opening Bell - Nasdaq
Biotech IPO Shares Climb in Debuts After Deals Upsized - MSN
TPG GP A, LLC Acquires New Stake in Bicara Therapeutics Inc - GuruFocus.com
James E. Flynn Buys 70,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock - Defense World
Ra Capital Management, L.P. Purchases 1,833,000 Shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) Stock - Defense World
Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com Canada
Ra capital executives buy Bicara Therapeutics shares for $32.99m - Investing.com India
Ra capital executives buy Bicara Therapeutics shares for $32.99m - Investing.com
Ra capital executives buy Bicara Therapeutics shares for $32.99m By Investing.com - Investing.com UK
FMR LLC Acquires New Stake in Bicara Therapeutics Inc - Yahoo Finance
FMR LLC Acquires New Stake in Bicara Therapeutics Inc - GuruFocus.com
Bicara Leads Trio of US Biotech IPOs Raising $703 Million - MSN
Deerfield entities buy Bicara Therapeutics shares worth $1.26m By Investing.com - Investing.com Australia
Deerfield entities buy Bicara Therapeutics shares worth $1.26m - Investing.com
Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity - Yahoo Finance
Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity - Pharmaceutical Technology
MBX, Zenas And Bicara IPOs Generate Big First Day Returns, But Will They Last? - Scrip
Bicara Therapeutics Announces Closing of $362 Million - GlobeNewswire
Bicara Therapeutics Announces Closing of $362 Million Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - StockTitan
Bicara, MBX Bio lead gainers as biotech trio makes trading debut - MSN
TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut - MSN
Biotech IPOs Surge on Debut: Upsized Deals Boost Shares for Drug Developers Tackling Autoimmune Diseases - Share Price India News
Trio of first-day pops may bode well for biotech IPO window - BioCentury
Bicara Therapeutics Opens at $26.25 , Upsized IPO Priced at $18 By Investing.com - Investing.com Canada
Biotech IPO Shares Climb in Debuts After Deals Upsized - Bloomberg
2 Life Sciences Cos. Start Trading After Raising $540M Total - Law360
TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut - KFGO
Bicara Therapeutics Rises 39% in Debut on Nasdaq - MarketWatch
3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders - MedCity News
Shares of two Mass. biotech IPOs rise on first day of trading - The Business Journals
Bicara, MBX Bio lead gainers among biotech IPOs (NASDAQ:BCAX) - Seeking Alpha
TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut - Reuters
Biotech IPO Shares Climb in Debuts After Deals Upsized - BNN Bloomberg
TPG-backed Bicara Therapeutics shares surge 46% in stellar market debut - WDKE 96.1 Duke FM
TPG-backed Bicara Therapeutics raises $315 mln in US IPO - Reuters
Two local biotechs go public, raising $540 million total - The Boston Globe
3 Biotechs Seek Over $700M in Renewed IPO Rush - BioSpace
Two local biotechs pull in $540M in IPOs - The Business Journals
Bicara Leads Trio of US Biotech IPOs Raising $703 Million - Yahoo Finance
Bicara Leads Trio of US Biotech IPOs Raising $703 Million - Bloomberg
Three biotechs raise $700M in rare burst of IPO activity - BioPharma Dive
Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering - ForexTV.com
BCAXBicara Therapeutics Inc. Latest Stock News & Market Updates - StockTitan
Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering - StockTitan
Bicara Therapeutics Announces Pricing Of Upsized Initial Public Offering - XM
Bicara Therapeutics Announces Pricing of Upsized Initial Public Offering - GlobeNewswire
Three biotechs raise $700M in rare burst of IPO activity - Yahoo Finance
Boston biotech increases target for pending IPO - The Business Journals
Bicara Therapeutics targets $265 million proceeds in upsized US IPO - KFGO
Bicara Therapeutics Inc Stock (BCAX) Financials Data
There is no financial data for Bicara Therapeutics Inc (BCAX). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):